, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, 

 covers every angle of oncology practice, from new technologies, to treatment advances, to important regulatory decisions. 

In today's episode, we spoke with Brian Druker, MD, of Oregon Health & Science University. 

In our exclusive interview, Druker discussed his journey into the field of oncology, the research that led to the initial approval of imatinib (Gleevec), why awards don’t impact his view on cancer care, and how becoming a family man has made him a better physician and scientist.


Podcasts

that provides oncology professionals with the resources and information they need to provide the best patient care. Segments cover every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. New episodes with exclusive interviews with leading oncology experts are released on Mondays and Thursdays. 

Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Marvels in Medicine

In our exclusive interview, Brian Druker, MD, discusses his journey into the field of oncology, the research that led to the initial approval of imatinib, why awards don’t impact his view on cancer care, and how becoming a family man has made him a better physician and scientist. 


Druker Details a Career of Determination, Patient Impact, and Family Success